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Abstract
Introduction: Recurrent hypoxia, which is associated with obstructive sleep apnea syndrome (OSAS), leads to an increase in
the degradation of adenosine triphosphatase into xanthine, which in turn increases uric acid concentrations.
Objective: The current study aimed to determine whether an association exists between OSAS and uric acid levels in the
peripheral blood from a representative population of Sao Paulo (Brazil).
Methods: A population-based survey adopting a probabilistic 3-stage cluster sample of Sao Paulo was used to represent the
population according to gender, age, and socioeconomic class. A total of 1,042 volunteers underwent polysomnography
recordings for OSAS diagnosis, blood pressure assessment, and biochemical blood analysis, and answered questionnaires.
Results: Uric acid levels were correlated with most important risk factors for OSAS, such as AHI, desaturation time and index,
minimum oxyhemoglobin saturation (SpO2), blood pressure, cholesterol, BMI, triglycerides and arousal, and with OSAS itself.
Also, uric acid was increased in OSAS volunteers even after controlling for all confounders. Hyperuricemic volunteers
presented lower mean and minimum SpO2 and increased desaturation index. Importantly, minimum SpO2 was a significant
predictor of uric acid levels, which in turn was considered an independent predictor for OSAS in the binary logistic model.
However, a ROC curve analysis for establishing cut-off points for uric acid levels as a biomarker of OSAS revealed moderate
sensitivity and specificity.
Conclusion: A strong association was found between uric acid levels and OSAS in a representative sample of the population
of Sao Paulo. Although they do not qualify for a biomarker alone, uric acid levels may be involved in OSAS severity and
should be considered in sleep apnea management in the future.
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Introduction
Obstructive sleep apnea syndrome (OSAS) is a highly prevalent
disorder affecting 2 to 33% of the population [1,2] (depending on
study methodology) and is associated with sympathetic activation,
metabolic dysregulation, and neurocognitive changes [3,4]. OSAS
is characterized by recurrent apneas associated with cyclic changes
in oxyhemoglobin saturation (SpO2) and alterations in heart rate
as well as in blood pressure during sleep [5,6,7]. Epidemiologic
evidence has confirmed that OSAS drastically promotes cardio-
vascular risks independent of age, sex, race, and other common
risk factors for cardiovascular diseases such as smoking, drinking,
diabetes mellitus, obesity, dyslipidemia, and hypertension (for
review, see [8]). Indeed, patients with severe OSAS display a
higher prevalence of coronary artery disease, heart failure, and
stroke (for review, see [9]).
It is well known that the repeated upper airway obstruction
episodes during OSAS produce an intermittent state of hypercap-
nia and hypoxia, which is accompanied by decreased blood
oxygen saturation and arousals during sleep [10]. Of note, these
multiple cycles of hypoxia/reoxygenation are associated with
increased production of reactive oxygen species (ROS), and can
alter the integrity of cellular metabolic processes [11]. Inadequate
oxygen supplies can impair the formation of adenosine triphos-
phate (ATP), an important compound for cellular homeostasis. In
response, this leads to a net degradation of ATP to adenosine
diphosphate and adenosine monophosphate [12]. Thus, this
process causes the release of purine intermediates (adenosine,
inosine, hypoxanthine and xanthine), ending with an overproduc-
tion of uric acid, the purine final catabolic product. As a
consequence, high levels of ATP degradation products have been
suggested as potential markers of tissue hypoxia in neonates with
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infant respiratory distress syndrome [13,14], ill patients [15,16],
exercising individuals [17,18] and pulmonary hypertension
patients [19].
Hyperuricemia has also been associated with heart failure,
multiple proaterogenic processes, and hypertension [20,21], and is
considered an independent predictor of death in patients at high
risk of cardiovascular disease [22]. In addition, Sahebjami [11] has
shown that uric acid excretion is increased in OSAS patients and
normalized after continuous positive airway pressure (CPAP)
treatment, most likely reflecting an association between hyperuri-
cemia and OSAS. Additional studies have also contributed to the
hypothesis that uric acid levels and sleep-disordered breathing are
related, although none have evaluated these parameters in a large
and representative population [23,24,25]. Uric acid formation is a
result of the activity of xanthine oxidase, an enzyme that plays a
mechanistic role in oxidative stress and cardiovascular diseases. Its
production is accompanied by the enhanced synthesis of ROS,
which play a significant role in hypoxia-related tissue damage [26].
Considering that the responses to the nocturnal hypoxemia
accompanying OSAS may vary among different populations, the
aim of this study was to elucidate the possible association between
uric acid levels and OSAS through hypoxia-related parameters
such as apnea-hypopnea index (AHI), SpO2 and desaturation
index during sleep in an epidemiological sample of Sao Paulo.
Moreover, we aimed to understand the possible role of uric acid as
a biomarker of OSAS, since inexpensive methods of excluding
significant sleep-disordered breathing such as sleep apnea are
desirable.
Materials and Methods
Ethics Statement
The study was approved by the local ethical committee (CEP
0593/06) and registered with ClinicalTrials.gov (Identifier
NCT00596713), following the principles of the Declaration of
Helsinki [27].
The Population Investigated
The Epidemiologic Sleep Study (EPISONO) is a large
epidemiological study examining sleep disturbances and their risk
factors. The investigation was performed in the city of Sa˜o Paulo,
Brazil. When the EPISONO was conducted (2007), Sa˜o Paulo had
more than 10 million inhabitants. Complete rational design,
sampling, and procedures have been described previously [28].
Figure 1. Serum uric acid levels in control (CTRL) and
obstructive sleep apnea syndrome (OSAS) groups stratified
by gender. Data are shown as mean6SEM. *p,0.0001 compared to
respective CTRL group; #p,0.0001 compared to women gender.
doi:10.1371/journal.pone.0066891.g001
Figure 2. Adjusted mean±SEM of uric acid levels (mg/dL)
covariated by body mass index (BMI)-categorical, age-categor-
ical, gender, race-ethnicity, social class and other cardiovas-
cular risk factors (SBP, cholesterol, LDL, HDL, triglycerides and
glicemia) in control (CTRL) and obstructive sleep apnea
syndrome (OSAS) groups. *p,0.05 compared to CTRL group.
doi:10.1371/journal.pone.0066891.g002
Table 1. Clinical presentation and demographic parameters
in the epidemiological sample of Sao Paulo according to
OSAS and CTRL groups (N = 1021).
CTRL SAOS p
Clinical presentation
Age (years) 38.460.5 50.860.7* ,0.0001
BMI (kg/m2) 25.460.2 29.760.3* ,0.0001
SBP (mmHg) 119.861.0 135.561.5* ,0.0001
DBP (mmHg) 76.960.6 84.060.9* ,0.0001
Apnea-hypopnea index 1.960.1 20.560.9* ,0.0001
Uric acid (mg/dL) 4.960.1 5.760.1* ,0.0001
Gender (%)
Men 25.9 18.8* ,0.0001
Women 40.9 14.4
Ethinicity (%)
Caucasian 36.2 21.5*
Afro-Brazilian 9.4 4.2
Mulatto 9.8 2.4 ,0.01
Asian 2.1 0.8
Native 2.2 0.9
Unknown/other 7.0 3.4
Socioeconomic status (%)
High-income 16.6 11.8*
Middle-income 43.1 18.8 ,0.001
Low-income 7.1 2.6
SBP = systolic blood pressure; DBP = diastolic blood pressure; BMI = body mass
index.
*mean or frequency significantly increased when compared to respective CTRL
group.
doi:10.1371/journal.pone.0066891.t001
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Briefly, this single center study included a total of 1,101 volunteers
(men and women) from Sa˜o Paulo. The selection of subjects was
performed according to the 3-stage cluster sampling technique to
obtain a representative sample from Sa˜o Paulo as previously
described [28].
At the time of selection, the volunteers signed the informed
consent form and answered the home questionnaires. Of these,
1,042 agreed to undergo polysomnography (PSG); a small amount
of volunteers (5.4%) refused the PSG test. Age, gender, and socio-
economic status distributions did not significantly differ between
the volunteers who accepted PSG recording and those who
refused. The subjects arrived 2 hours before bedtime at the Sleep
Institute and answered institutional questionnaires. Volunteers
underwent a complete overnight PSG and blood samples were
collected for biochemical analysis the following day. Those who
were receiving uric acid-lowering medications (such as allopurinol
or probenecid), which may impact uric acid levels, were excluded
from the present analysis, totaling 1,021 volunteers.
Physical Measurements
General physical measurements were taken immediately before
the subjects were prepared for the PSG hook-up, following
recommended procedures and utilizing precise instruments.
Measurements were taken by 2 trained physical education teachers
and included systolic blood pressure (SBP, mmHg), diastolic blood
pressure (DBP, mmHg), body weight (kg), height (m) and
calculation of body mass index (BMI) using the formula (weight/
height2).
Polysomnography
A full-night PSG was performed using a digital system
(EMBLAH S7000, Embla Systems, Inc., Broomfield, CO., USA)
at the sleep laboratory during the subject’s habitual sleep time
according to previously described [1]. The following physiological
variables were monitored simultaneously and continuously: 4
channels for the electroencephalogram (EEG); 2 channels for the
electrooculogram; 4 channels for the surface electromyogram
(submentonian region, anterior tibialis muscle, masseter region,
and seventh intercostal space); 1 channel for an electrocardiogram;
airflow detection via 2 channels through a thermocouple (one
channel) and nasal pressure (one channel); respiratory effort of the
thorax (one channel) and of the abdomen (one channel) using
inductance plethysmography; snoring (one channel) and body
position (one channel); oxyhemoglobin saturation (SpO2, percent-
age of available hemoglobin that is saturated with oxygen
estimated by pulse oximetry); and pulse rate. Desaturation time
was calculated through the cumulative percentage sleep time with
SpO2#90%. Oxygen desaturation index was calculated by
dividing the total number of oxygen desaturations by the total
sleep time, with desaturation defined as a $10s reduction in SpO2
($4% of baseline at the nadir), independent of airflow or
thoracoabdominal movement.
Figure 3. Adjusted mean±SEM of apnea-hypopnea Index (AHI, n =1020, A), mean oxyhemoglobin saturation (SpO2, n=1020, B),
minimum SpO2 (n=1020, C), desaturation index (n=843, D) and desaturation time (n=996, E) covariated by gender, body mass
index (BMI)-categorical and age-categorical in normouricemic and hyperuricemic groups. Data are shown as Mean 6 SEM. *p,0.05
compared to normouricemic group.
doi:10.1371/journal.pone.0066891.g003
Figure 4. Frequency of normouricemia (n=849) and hyperuri-
cemia (n=172) in control (CTRL, n=682) and obstructive sleep
apnea syndrome (OSAS, n=339) volunteers. Significant associa-
tion between OSAS and hyperuricemia.
doi:10.1371/journal.pone.0066891.g004
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Four trained technicians visually scored all PSGs according to
standardized criteria for investigating sleep [29]. EEG arousals
and leg movements were scored according to the criteria
established by the AASM Manual for Scoring Sleep and
Associated Events [30]. Apneas were scored and classified
following the recommended respiratory rules for adults suggested
by the AASM Manual, and hypopneas were scored according to
the alternative rules [30]. A registered PSG technologist randomly
selected and rescored the sleep stages of 4% of the PSGs in order
to verify their accuracy (agreement rate of 93.365.1%,
k= 0.9160.03).
Clinical Assessment
OSAS was diagnosed according to the criteria of the
International Classification of Sleep Disorders (ICSD-2) proposed
by American Academy of Sleep Medicine (AASM) [31]. Subjects
were diagnosed with OSAS if they had 5#AHI#14.9 and
presented at least one of the following complaints: loud snoring,
daytime sleepiness, fatigue, and breathing interruptions during
Figure 5. Receiver-operating characteristics (ROC) curve analysis comparing serum uric acid levels and apnea-hypopnea index
(AHI) as classifiers for obstructive sleep apnea syndrome (OSAS) diagnostic.
doi:10.1371/journal.pone.0066891.g005
Table 2. Pearson’s correlation coefficients between serum uric acid and risk factors distributed by gender.
Men Women Total population
R p N R P N R P N
Age 0.17 ,0.0001 456 0.27 ,0.0001 565 0.13 ,0.0001 1021
AHI 0.16 ,0.0001 456 0.22 ,0.0001 565 0.25 ,0.0001 1021
Arousal index 0.11 ,0.05 456 0.13 ,0.01 565 0.19 ,0.0001 1021
BMI 0.35 ,0.0001 455 0.45 ,0.0001 565 0.31 ,0.0001 1021
Cholesterol 0.21 ,0.0001 456 0.18 ,0.0001 565 0.14 ,0.0001 1021
Creatinine 0.23 ,0.0001 456 0.26 ,0.0001 565 0.49 ,0.0001 1021
Desaturation index 0.15 ,0.0001 416 0.24 ,0.0001 428 0.21 ,0.0001 844
Desaturation time 0.10 ,0.05 445 0.14 ,0.001 552 0.11 ,0.0001 997
Glucose 0.14 ,0.0001 455 0.16 ,0.0001 565 0.15 ,0.0001 1020
HDL 20.17 ,0.0001 456 20.16 ,0.0001 565 20.34 ,0.0001 1021
LDL 0.10 ,0.05 444 0.16 ,0.0001 563 0.11 ,0.0001 1007
Minimum SpO2 20.20 ,0.0001 456 20.33 ,0.0001 565 20.28 ,0.0001 1021
SBP 0.27 ,0.0001 441 0.29 ,0.0001 551 0.28 ,0.0001 992
Sodium 0.07 .0.05 454 0.11 ,0.01 559 0.11 ,0.001 1013
Triglycerides 0.33 ,0.0001 456 0.29 ,0.0001 565 0.37 ,0.0001 1021
doi:10.1371/journal.pone.0066891.t002
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sleep. Subjects with an AHI$15 were diagnosed with OSAS
regardless of whether they had any additional complaints. Loud
snoring was assessed using the second question of the Berlin
Questionnaire for sleep apnea [32]: a positive response included
snoring that was ‘‘louder than talking’’ or ‘‘very loud – can be
heard in adjacent rooms.’’ Daytime sleepiness was assessed using
the Epworth Sleepiness Scale [33] and the 8 questions of the
Pittsburgh Sleep Quality Index [34]; Epworth scores higher than 9
and/or frequencies greater than once a week according to the
Pittsburgh Index were considered to be positive. Fatigue was
assessed with the Chalder Fatigue Scale [35], and scores higher
than 4 were considered to be positive. Breathing interruptions
were assessed using the fifth question of the Berlin Questionnaire
[32] and were considered to be positive when the frequency was
‘‘higher than once a month.’’
Ethnicity and Social Class
Individuals self-reported their ethnic origin according to the
following classifications used by the Brazilian Institute of
Geography and Statistics (IBGE): Caucasian, Afro-Brazilian,
Mixed Race (mulattos), Asian, Native (indigenous), and un-
known/other. Social class was defined as high, middle, or low
according to the Brazilian Economic Classification Criteria (www.
abep.org), as household incomes greater than $15,961 (US dollars),
between $4561 and $15,960, and lower than $4560 per year,
respectively.
Sample Collection and Biochemical Analysis
Approximately 45 mL of venous blood was collected from
subjects’ forearms after 12 hours of overnight fasting. After
collection, the tubes were centrifuged at 3,500 rpm for 10 minutes.
Serum was kept at room temperature and plasma was stored at
4uC. The blood analysis included the following blood exams: uric
acid, creatinine, glucose, total cholesterol and its fractions (LDL
and HDL), triglyceride, sodium (Na+) and potassium (K+) levels.
All were obtained through automated dosages with an AdviaH
1650 chemistry system (Siemens Healthcare Diagnostics Inc.,
USA).
Statistical Analysis
All data that did not met the assumptions of normality and
homogeneity were Z-score transformed for suitable parametric
evaluation. Analyses of covariance (ANCOVA) were used to
investigate the effects of OSAS on uric acid levels with control for
the confounding variables: BMI, age, gender, social class,
ethnicity, and cardiovascular risk factors (SBP, DBP, cholesterol
and fractions, triglycerides and glucose levels). To evaluate the
relationship between uric acid levels and OSAS-related risk
factors, a Pearson correlation test was performed. To determine
the possible predictors of uric acid levels in men, women and the
total population, all the variables which presented a significant
correlation with uric acid were included in a multiple linear
regression model using the stepwise procedure. A Chi-square test
was performed to determine the association between uricemia
(normouricemic or hyperuricemic) and OSAS. Hyperuricemia was
defined by the concentration $95th percentile of the normal
distribution curve by gender. Then, binary logistic regression was
used to reveal the predictors of OSAS using the backward-
conditional method and Hosmer-Lemeshow goodness-of-fit. The
categorical variables chosen for the logistic regression were:
gender, age (#43 or .43 years), and BMI (#26.8 or .26.8 kg/
m2). The continuous variables chosen for the logistic regression
were: SBP, uric acid, total cholesterol, LDL, HDL, triglycerides
and glucose. In addition, a receiver-operating characteristics
(ROC) curve was used to determine the optimal cut-off point for
uric acid as a classifier of OSAS (according to the highest
sensitivity and specificity). Significance level was set at 5%. Data
are reported as means 6 standard error of the mean (SEM). All
analyses were performed using SPSS 17 (SPSS Inc., Chicago, IL,
USA).
Results
Of the 1,042 volunteers enrolled in the study, 21 were excluded
for taking medication that could affect uric acid levels. Thus, 1,021
Table 3. Multiple linear regression for uric acid levels
predictors in men (n = 437). SBP = systolic blood pressure;
SpO2 = oxyhemoglobin saturation.
b t p
Constant 8.08 ,0.0001
Triglycerides 0.28 6.55 ,0.0001
Creatinine 0.20 4.49 ,0.0001
SBP 0.16 3.44 ,0.001
Potassium 2 0.13 2 2.93 ,0.01
Minimum SpO2 2 0.13 2 2.84 ,0.01
doi:10.1371/journal.pone.0066891.t003
Table 4. Multiple linear regression for uric acid levels
predictors in women (n = 550).
b t p
Constant 210.19 ,0.0001
BMI.26.8 kg/m2 0.25 5.79 ,0.0001
Creatinine 0.20 5.38 ,0.0001
Minimum SpO2 2 0.15 2 3.56 ,0.0001
Triglycerides 0.12 3.11 ,0.01
SBP 0.11 2.71 ,0.01
SBP = systolic blood pressure; SpO2 = oxyhemoglobin saturation; BMI = body
mass index.
doi:10.1371/journal.pone.0066891.t004
Table 5. Multiple linear regression for uric acid levels
predictors the total sample population (n = 992).
b t p
Constant 10.10 ,0.0001
Gender (men) 0.36 12.23 ,0.0001
Creatinine 0.21 7.04 ,0.0001
Triglycerides 0.18 7.18 ,0.0001
BMI.26.8 kg/m2 0.13 5.03 ,0.0001
SBP 0.11 4.30 ,0.0001
Minimum SpO2 2 0.10 2 3.82 ,0.0001
Potassium 2 0.06 2 2.61 ,0.01
SBP = systolic blood pressure; SpO2 = oxyhemoglobin saturation; BMI = body
mass index.
doi:10.1371/journal.pone.0066891.t005
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were included in the current study. From these, 177 were missing
desaturation index; 29 were missing SBP and DBP; 24 were
missing desaturation time; 14 were missing triglycerides and LDL;
8 were missing Na+ and K+ levels; and 1 was missing glucose and
BMI data. Of the 1,021 participants, 456 (44.7%) were men and
565 (55.3%) were women. Mean 6 SEM age was 42.560.5 years
and mean BMI was 26.860.2 kg/m2. Of the 1021 volunteers, 321
were hypertensive (defined as systolic blood pressure equal to and
greater than 140 mmHg and/or diastolic blood pressure equal to
and greater than 90 mmHg) and 68 reported using an antihyper-
tensive. However, there was no significant effect on uric acid levels
between hypertensive and non-hypertensive as well as antihyper-
tensive users and non-users.
Table 1 illustrates the most important clinical and demographic
data in CTRL and OSAS groups (not controlled for confounder
variables). Figure 1 shows that the ANOVA revealed group
(F1,1017 = 47.06; p,0.0001) and gender (F1,1017 = 356.83;
p,0.0001) effects, showing that uric acid levels were higher in
the OSAS group compared to the control (CTRL) group
independent from gender. Also, the levels of uric acid were always
higher in men than in women. However, after controlling for BMI
and age, the group effect was no longer significant. As the groups
were not BMI- and age-matched, we determined the cut-offs for
these covariates, i.e., the values from which they statistically
affected the analysis as a confounding variable. Thus, these values
were used to stratify the population sample into binary groups and
reduce or eliminate the influence of BMI and age in the analysis to
better describe the results. Thus, using ANCOVA, the values of
the covariates appearing in the model were 26.8 kg/m2 for BMI
and 43 years old for age. Next, we categorized these variables in 2
bands (15.1–26.8 kg/m2 and 26.9–55.0 for BMI-categorical; 20–
43 years old and 44–80 years old for age-categorical). Then,
following the same rationale, we proceeded to perform another
ANCOVA test controlling for BMI-categorical, age-categorical,
gender, ethnicity, social class and other cardiovascular risk factors
(SBP, cholesterol, LDL, HDL, triglycerides and glucose). The
results still revealed a significant group effect (F1,956 = 3.65;
p,0.05), confirming that the OSAS group presented higher levels
of uric acid compared to the CTRL group even after control for all
confounding factors (Figure 2).
To further evaluate the relationship between uric acid levels and
OSAS, we first categorized the uric acid variable into high or low
levels. In this sense, hyperuricemia was defined by the concentra-
tion $95th percentile of the normal distribution curve by gender.
The 95% uric acid values were 7.0 mg/dL in men and 5.7 mg/dL
in women. Overall, the prevalence of hyperuricemia was 16.8%,
higher in men (9.8%) than in women (7.0%, x2 = 15.20, df = 1,
p,0.0001). Figure 3 shows the effects of uricemia, controlled for
BMI-categorical, age-categorical, and gender on 5 variables
strongly associated with OSAS: AHI (A), mean SpO2 (B),
minimum SpO2 (C), desaturation index (D) and desaturation time
(E). Despite the trend for increased AHI in the hyperuricemic
compared to normouricemic group, no significant differences were
observed (F1,1015 = 3.45, p = 0.06) (Figure 3A). Importantly,
ANCOVA analysis revealed an effect of uricemia on the mean
SpO2 (F1,1015 = 6.14, p,0.05), demonstrated by a reduction in the
hyperuricemic compared to the normouricemic group (Figure 3B).
Similarly, a significant uricemia effect was found on the minimum
SpO2 (F1,1015 = 13.32, p,0.0001), showing a decrease in hyper-
uricemic compared to normouricemic group (Figure 3C). Regard-
ing the desaturation index, ANCOVA analysis also demonstrated
an uricemia effect (F1,838 = 4.13, p,0.05) with increased desatu-
ration index in the hyperuricemic group when compared to the
normouricemic (Figure 3D). No differences were found in the
desaturation time (F1,991 = 1.54, p.0.05) (Figure 3E).
In addition, we found a significant association between
hyperuricemia and the presence of OSAS (x2 = 40.6, df = 1,
p,0.0001, N = 1021). Figure 4 shows that 54% of hyperuricemic
volunteers also had OSAS compared to 29% of normouricemic
volunteers. To establish the possible predictors of uric acid levels
that could be contributing to the association of hyperuricemia and
OSAS, we calculated a correlation matrix between uric acid and
all sleep, physical and circulating parameters collected (data not
shown). Table 2 shows the correlation coefficients of uric acid
levels with the most relevant risk factors after the analysis, which
were: age, AHI, arousal index, BMI, total cholesterol and
fractions, creatinine, desaturation index and time, glucose,
Table 6. Binary logistic regression model for calculation of
the odds ratio (OR) related to the obstructive sleep apnea
syndrome (OSAS) condition.
OR p 95% C.I. for OR
Lower Upper
Constant 0.001 ,0.0001 – –
Uric acid 1.16 ,0.05 1.01 1.33
Age.43 years 4.52 ,0.0001 3.18 6.42
BMI.26.8 kg/m2 3.21 ,0.0001 2.28 4.52
Gender (men) 2.58 ,0.0001 1.71 3.87
SBP – .0.05 1.00 1.01
Cholesterol – .0.05 0.35 1.05
HDL – .0.05 0.95 2.84
LDL – .0.05 0.96 2.86
Triglycerides – .0.05 0.99 1.23
Adjusted model for the confounding factors: age.43 years, body mass index
(BMI).26.8 kg/m2, gender (reference for men), systolic blood pressure (SBP),
cholesterol, LDL, HDL and triglycerides (N = 977).
doi:10.1371/journal.pone.0066891.t006
Table 7. Areas under the ROC curves (AURC), cut-offs, sensitivity and specificity of serum uric acid levels in relation to the ability to
identify obstructive sleep apnea syndrome (OSAS).
Variable AURC SEM p 95% C.I. Cut off Sensitivity Especificity
Men Uric acid 0.63 0.026 ,0.0001 0.58–0.68 5.95 0.62 0.57
AHI 0.98 0.005 ,0.0001 0.97–0.99
Women Uric acid 0.64 0.028 ,0.0001 0.58–0.69 4.45 0.63 0.64
AHI 0.98 0.004 ,0.0001 0.98–0.99
doi:10.1371/journal.pone.0066891.t007
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minimum SpO2, SBP, Na
+ and triglycerides. Overall, we observed
a slight positive correlation of uric acid levels with age, arousal
index, total cholesterol, desaturation index, glucose, LDL and Na+
in the total population. Moreover, a mild positive correlation was
observed between uric acid and AHI, BMI, SBP and triglycerides.
On the other hand, a mild negative correlation was found between
uric acid and HDL and minimum SpO2. A moderate positive
correlation was only observed between uric acid levels and
creatinine in the total population sample (R = 0.49, p,0.0001).
Next, a multiple linear regression model was performed to identify
the possible predictors of uric acid levels in men, women and the
total population sample. Importantly, Table 3 shows that in men
triglycerides, creatinine, SBP, K+ and minimum SpO2 entered
into the model explaining 22% of uric acid variability (R = 0.47,
R2 = 0.22, F5,437 = 24.63, p,0.0001, Table 3). In women, the
BMI.26.8 kg/m2, creatinine, minimum SpO2, triglycerides and
SBP entered into the model explaining 27% of uric acid variability
(R = 0.52, R2 = 0.27, F5,544 = 39.32, p,0.0001, Table 4). Consid-
ering the total population, the significant predictors of uric acid
levels were gender (men), creatinine, triglycerides, BMI.26.8 kg/
m2, SBP, minimum SpO2, and K
+ level (R = 0.68, R2 = 0.46,
F7,982 = 120.63, p,0.0001, Table 5).
Finally, to verify whether uric acid levels could be, in turn, a risk
factor for OSAS in our sample population, a binary logistic
regression analysis was performed. Table 6 depicts the model with
the most favorable Hosmer-Lemeshow goodness-of-fit (x2 = 4.48,
df = 8, p.0.05) and the corresponding odds ratio (OR) of each
independent predictor of OSAS (22LL = 961.50; x2 = 274.24,
df = 9, p,0.0001; Cox-Snell R = 0.25; Nagelkerke R = 0.34):
age.43 years, BMI.26.8 kg/m2, gender (men) and uric acid
levels. Importantly, the results show that an increase in 1 mg/dL
in uric acid level was associated with 16% increased risk of OSAS
(95% C.I. = 1.01–1.33). The other variables, SBP, cholesterol,
HDL, LDL and triglycerides, did not enter the model. Figure 5
and Table 7 show the areas under the ROC curves (AURC) and
the optimal cut-off points (according to the highest sensitivity and
specificity) of uric acid levels associated with OSAS diagnosis. The
best cut-offs were 5.95 mg/dL for men and 4.45 mg/dL for
women, which were in the 50th percentile of the uric acid
distribution curve and corresponded respectively to a positive
predictive value (PPV) and negative positive value (NPV) of 61.0%
and 55.7% in men and 37.8% and 82.1% in women.
Discussion
This is the first study showing the influence of OSAS on uric
acid levels in an epidemiological sample. Interestingly, the results
indicate that individuals diagnosed with OSAS had higher levels of
serum uric acid than those without OSAS. Additionally, this effect
remained significant after adjustment for confounding factors such
as gender, age, BMI, social class, ethnicity, cholesterol, triglycer-
ides, blood pressure and glucose, unlike the data published by
Garcı´a et al. [25]. Moreover, a higher prevalence of hyperurice-
mia was found in men, which is also the gender with more
prevalence of OSAS [1,2].
We also demonstrated important associations between uric acid
levels and common OSAS-related risk factors such as SpO2, AHI,
arousal index, desaturation, cholesterol and fractions, triglycerides,
SBP and BMI in this large sample. Similarly, our data showed that
hyperuricemic volunteers, regardless of OSAS diagnosis, presented
lower mean and minimum SpO2, and higher desaturation index
during sleep, explaining the strong association found between
hyperuricemia and OSAS. Additionally, uric acid was considered
an independent predictor of OSAS, being associated with 16%
increased risk of OSAS with each increase of 1 mg/dL in its
concentration. Conversely, minimum SpO2 entered the multiple
linear regression model as an independent predictor of uric acid
levels explaining 10% of its variability, along with other factors
such as gender (men), creatinine, triglycerides, BMI.26.8 kg/m2,
SBP and serum K+ levels. On the other hand, ROC curve analysis
revealed that, in both men and women, uric acid levels cut-off
points determined through its highest sensitivity and specificity did
not qualify for a good biomarker of OSAS, presenting poor PPV
and NPV.
A large body of evidence has identified OSAS as an
independent risk factor for cardiovascular morbidity and mortality
with multiple associated mechanisms [8]. One of them is the
oxidative stress [36], which is also a common pathway linked to
uric acid production, a process catalyzed by xanthine oxidase [37].
During the production of uric acid, ROS are generated as
byproduct and have an important role in the increased vascular
oxidative stress. Importantly, xanthine oxidase mediates intermit-
tent hypoxia-induced vascular dysfunction and administration of
allopurinol can prevent it by increasing intermediates, hypoxan-
thine and xanthine, and decreasing the final product uric acid
[38,39]. In fact, oxidative stress is reflected by uric acid levels, and
its concentration decreases after treatment of sleep disordered
breathing according to improvement of respiratory disturbance
index and oxygen desaturation index [40]. Elevated serum uric
acid levels are also associated with increased risk for cardiovascular
mortality [21,41,42]. In fact, most of the cardiovascular risk factors
potential overlaps with serum uric acid levels concentrations
[43,44,45]. In this sense, a positive association of hyperuricemia
with obesity, impaired glucose tolerance, hypertension, history of
heart disease and mortality was observed in a large Finland cohort
population (aged 40–69) [43]. Moreover, some studies have
reported that elevated levels of uric acid are associated not only
with the presence of cardiovascular disease but also with poor
prognosis of stable coronary artery disease [46], acute myocardial
infarction [47,48,49], heart failure [50], stroke [51], and metabolic
syndrome [52].
Corroborating Jubber and colleagues [53], we also found an
association between BMI and elevated blood concentrations of
uric acid. Both hyperuricemia and excessive accumulation of body
fat are known to be associated with greater cardiovascular risk and
oxidative stress [25,26,54], suggesting that uric acid may have an
important role in mediating OSAS in obese patients. Similarly,
Verhulst et al. [54] have demonstrated a relationship between the
severity of sleep apnea and increased levels of serum uric acid in
overweight children and adolescents, independent of abdominal
adiposity. In fact, obese individuals present a higher incidence of
respiratory diseases, including OSAS, which contributes to
increased morbidity and mortality among this population [55,56].
Confirming our hypothesis, the linear regression model
presented in the current study showed important participation of
the minimum SpO2 in the uric acid levels even after control for
confounders such as BMI. Moreover, triglycerides and hyperten-
sion also participated as important predictors of the uric acid levels
in agreement with some previews studies [57,58]. Recently, Desai
et al. [59] showed that a significant linear increase in uric acid
levels occurs with increasing metabolic risk factors in middle-aged
Brazilian men. Patients who had a high triglyceride/HDL ratio
had significantly higher serum uric acid levels than did those who
had a normal ratio. Taken together, these results reflect a close
relationship between uric acid levels and metabolic syndrome.
However, it is important to stress that the tissue hypoxia caused by
OSAS is determined by a complex balance between the supply of
arterial oxygen and tissue oxygen demand. Thus, arterial oxygen
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supply depends on other factors besides oxyhemoglobin saturation,
including hemoglobin concentration, the oxygen-hemoglobin
dissociation curve and cardiac output.
Similar to our data, some studies found increased uric acid
levels in OSAS patients compared to controls in addition to higher
levels of blood pressure, glucose, triglycerides, cholesterol and
LDL [60,61]. Drager et al. [61] showed that OSAS was also
independently associated with increased uric acid, but with a OR
of 4.19 (1.70–10.35), much higher than we found in the current
study, likely due to the different populations studied (all patients
selected by Drager et al. presented metabolic syndrome). More-
over, similar to our findings, Kaditis et al. [62] found that AHI
and SpO2 were related to uric acid excretion in Greek (but not
US) children even after adjustments for age, gender, and BMI Z-
score. Another study also found a significant correlation between
uric acid levels and some sleep,parameters (number of respiratory
events, number of desaturations, or the cumulative percentage of
time with oxygen saturation less than 90%) [25]. Additionally, they
showed that those patients with severe OSAS (AHI$30) had
higher uric acid levels than those with mild or no OSAS. However,
this difference was not persistent after control for the confounding
factors BMI, cholesterol and triglyceride levels [25]. Likewise, Hira
et al. [63] found a significant linear relationships of AHI with uric
acid while Steiropoulos and colleagues [64] showed that OSAS
patients with good compliance to CPAP presented a decrease in
uric acid levels after CPAP treatment when compared to those
with bad compliance.
Uric acid has been studied in several cardiorespiratory processes
that produce hypoxia since this condition leads to increased
catabolism of purines. In this sense, uric acid has shown useful as a
prognostic marker of heart failure [65], pulmonary thromboem-
bolism [66], and primary pulmonary hypertension [19]. A recent
study in chronic obstructive pulmonary disease patients using the
ratio between uric acid and creatinine has been shown to be more
useful than the use of serum uric acid levels alone [67]. However,
in our study we did not find the same result, since no significant
differences were found using the uric acid/creatinine ratio (data
not shown). Moreover, two studies using this method in OSAS
patients presented different results. Braghiroli et al. [68] concluded
that uric acid/creatinine ratio could be a promising index of
significant nocturnal tissue hypoxia, since their OSAS patients had
a marked reduction in the uric acid/creatinine ratio after
treatment with CPAP. On the other hand, McKeon et al. [69],
studying hypoxemic patients with OSAS before and after CPAP
treatment, did not find significant differences in the uric acid/
creatinine ratio. In addition, another study showed that the index
of uric acid/creatinine from OSAS patients did not parallel the
severity of the AHI or arterial oxygen desaturation, but it was
significantly linked to the plasma level of adenosine, which is
another marker of tissue hypoxia [12].
Our data indicate that increased uric acid may be an important
risk factor for the severity of OSAS, possibly by favoring oxidative
stress and endothelial dysfunction. Conversely, minimum SpO2
decrease, resultant from OSAS-hypoxia/reoxygenation cycles, is
an important predictor of uric acid levels and may be responsible
for the association found between hyperuricemia and OSAS in our
epidemiological sample of Sao Paulo. Nevertheless, the best cut-
offs for uric acid level as a classifier of OSAS presented around
60% sensibility and 60% specificity, indicating that it fails to be a
good biomarker by itself. Probably, a combination of OSAS-
related biological analytes rather than only one would be more
applicable as a potential biomarker.
Finally, the current study suggests that uric acid measurement
may be important in the management of OSAS and its
comorbidities, mainly where people do not have access to
health-care facilities and sleep laboratories. Since uric acid
overproduction is accompanied by an enhanced synthesis of
ROS, the current study may contribute to the mechanisms linking
sleep-disordered breathing and cardiovascular risk. However,
long-term epidemiological studies to verify the consequences of
decreasing uric acid concentration in OSAS patients and also to
evaluate uric acid levels changes after CPAP treatment are
needed.
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